Skip to main content
Log in

Delayed disposition of adriamycin and its active metabolite in haemodialysis patients

  • Letters To The Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sotherland GA, Glass J, Gabriel R (1977) Increased incidence of malignancy in chronic renal failure. Nephron 18: 182–184

    Google Scholar 

  2. Bachur NR (1979) Anthracycline antibiotic pharmacology and metabolism, Cancer Treat Rep 6: 817–820

    Google Scholar 

  3. Gibaldi M, Perrier D (1982) Application of pharmacokinetic principles and analysis based on statistical moment theory. In: Swarbruck J (ed) Pharmacokinetics, 2nd edn. Dekker, New York, pp 385–407 and pp 409–417

    Google Scholar 

  4. Evans WE, Crom WR, Yee GC, Green AA, Hayes FA, Pratt CB, Avery TL (1980) Adriamycin pharmacokinetics in children. Proc Am Assoc Cancer Res 21: 176

    Google Scholar 

  5. Loveless H, Arena E, Felted RL, Bachur NR (1978) Comparative mammalian metabolism of adriamycin and daunorubicin, Cancer Res 38: 593–598

    Google Scholar 

  6. Balis FM, Holcenberg JS, Bleyer WA (1983) Clinical pharmacokinetics of commonly used anticancer drugs, Clin Pharmacokinet 8: 202–232

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goto, M., Yoshida, H., Honda, A. et al. Delayed disposition of adriamycin and its active metabolite in haemodialysis patients. Eur J Clin Pharmacol 44, 301–302 (1993). https://doi.org/10.1007/BF00271378

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00271378

Key words

Navigation